Cargando…
Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
Approximately 15–20% of breast cancers (BC) demonstrate HER2 overexpression/gene amplification. Historically, before the era of HER2-directed therapies, this subtype was associated with poor prognosis. Anti-HER2 agents dramatically changed the natural course of disease and significantly prolonged pa...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643304/ https://www.ncbi.nlm.nih.gov/pubmed/37878202 http://dx.doi.org/10.1007/s11864-023-01137-5 |